Sanofi’s Sarclisa shows significant Phase III results for multiple myeloma, delivering deeper and longer-lasting responses in ...

New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MRD negativity rates in transplant-ineligible NDMM patients versus VRd alone New detailed results from ...

New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th ...

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients Paris, December 9, 2024. New data from three oral presentations, which demonstrated ...

New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MRD negativity rates in transplant-ineligible NDMM patients versus VRd alone New detailed results from the ...